RT Journal Article
SR Electronic
T1 611 XTX202–01/02–001, Phase 1/2 first-in human study of XTX202, a masked, tumor-activated IL-2βγ, in patients with advanced solid tumors: results from phase 1
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A695
OP A696
DO 10.1136/jitc-2023-SITC2023.0611
VO 11
IS Suppl 1
A1 Hanna, Diana
A1 Zakharia, Yousef
A1 Goel, Sanjay
A1 Hurley, Randy
A1 Pelster, Meredith
A1 El-Khoueiry, Anthony
A1 Thomas, Jacob
A1 Powderly, John
A1 Miller, David
A1 Wu, Richard
A1 Chmielowski, Bartosz
A1 Rapisuwon, Suthee
A1 Gupta, Anurag
A1 Duncan, Meghan
A1 Siu, Aika
A1 Patel, Ekta
A1 Fantini, Damiano
A1 Crowe, David
A1 Paramasivan, Sattanathan
A1 Lee, George
A1 Luptakova, Katarina
A1 McKean, Meredith
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A695.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.